INTRODUCTION
Hamberg and Samuelsson (1) have described the detection and isolation of the endoperoxide intermediate that gives rise to prostaglandin (PG)1 E2 and PGF2. during incubation of arachidonic acid with a preparation of sheep seminal vesicles. Since it has been established that human platelets form PGE2 and PGF2. during blood clotting (2, 3) and during platelet aggregation in response to ADP, L-epinephrine, or collagen (4, 5) , it was of interest to determine whether they also form this intermediate. Recently, it was shown that the precursor of PGE2 and PGF2., arachidonic acid, induces platelets to form prostaglandins and aggregate (6, 7) . The latter effect appears to be specific for arachidonic acid, since it does not occur in response to a number of related fatty acids (8) . The present studies show that the link beReceived for publication 20 September 1973 and in revised form 17 December 1973 . ' Abbreviations used in this paper: PG, prostaglandin;
PGD2, 11-dehydro-PGF21; PRP, platelet-rich plasma.
tween prostaglandin formation and aggregation is the platelet release reaction (see reference 9) and suggest that the endoperoxide intermediate may be its trigger.
METHODS
Platelet aggregation. Human blood was collected from the antecubital veins of healthy subjects into 0.1 vol of 3.8% trisodium citrate and was centrifuged to prepare platelet-rich plasma (PRP) as previously described (4).
Platelet aggregation was initiated by addition of up to 0.16 ml of the agent under study to 2 ml PRP stirred at 1,000 rpm in siliconized test tubes at 37'C. Aggregation was monitored by the continuous recording of light transmission (aggregometer from Chrono-Log Corp., Broomall, Pa.). Aggregating agents investigated were L-epinephrine hydrochloride (Sigma Chemical Co., St. Louis, Mo.), collagen suspension (bovine tendon [10] Corp., Arlington Heights, Ill.) at a final concentration of 0.5 ,uM. At appropriate times after initiating aggregation as described above, samples (1.5 ml) were rapidly decanted into 0.15 ml ice-cold, 0.1 M EDTA (pH 7.4) and mixed. The samples were further cooled in crushed ice and centrifuged for 1 min at 15,000 g (Eppendorf microfuge, Brinkmann Instruments, Inc., Westbury, N. Y.), and 0.2-ml samples of the supernatant fluid were taken to determine the release of adenine nucleotides and radioactivity (11) . Aggregation recordings in radioactive PRP were identical to those obtained with the same concentration of aggregating agent in nonradioactive PRP.
Preparation of samples for radioimmunoassay. At appropriate times after addition of an aggregating agent or saline, the contents of the aggregometer tube (2 ml PRP) were rapidly decanted into 10 ml ethanol, containing 0 (12) . The ,prostaglandins were separated into fractions containing E or F types by column chromatography on silicic acid (13) . These fractions were blown to dryness at 400C under a stream of nitrogen, suspended in 0.5 ml Tris-saline (0.015 M Tris-HCl, pH 7.5, 0.14 M NaCl) and kept for up to 1 wk at -300C.
Radioimmunoassay of prostaglandins. Samples containing F type prostaglandins were assayed in duplicate by employing a rabbit antiserum generated against PGFr. and using nitrocellulose membranes (14) . The sensitivity of this assay is illustrated in Fig. 1 , and the conditions are given in the legend. Prostaglandin levels were determined by interpolation from standard curves. PGE, was assayed indirectly, using the PGF2s antiserum, after reduction of PGE to PGF with sodium borohydride (15 * Since PGE2 is reduced to 50% PGF2g and 50% PGF29
(which does not cross react), the amount originally present as PGE2 is twice that shown.
Validation of methods. After addition of 0.9 pmol [3H]-PGE1, sp act 49 Ci/mmol, (New England Nuclear) to PRP, with extraction and chromatography as described above, 87.6% (SD 2.4) of the radioactivity eluted from the columns was present in the PGE fraction and 3.2%o (SD 1.7) was in the PGF fraction (20 determinations).
After addition of 7.5 pmol [3H]PGF2&, sp act 8.8 Ci/mmol, (New England Nuclear), 94.0% (SD 1.7) of the radioactivity was present in the PGF fraction, and 3.0% (SD 1.1) in the PGE fraction (18 determinations). These distributions of radioactivity were not altered by incubation of the prostaglandins in PRP for 15 min at 370C, confirming that E and F types of PG are relatively stable in plasma.
The validity of sodium borohydride reduction for the measurement of pure PGE2 by radioimmunoassay is illustrated in Fig. 2 , and the conditions of the reduction are given in the legend. In crude extracts from biological sources, this method would also measure 11-dehydro-PGF2a, which is almost exclusively converted to PGF2< by sodium borohydride reduction (1). However, 11-dehydro-PGF2, (PGD2) elutes before PGE2 from silicic acid columns (16) and therefore should not interfere in our estimations of PGE2 formation. This assumption was confirmed by the finding that radioimmunoassay and bioassay gave essentially the same values for PGE2 formation (cf. references 4 and 8).
Addition of known amounts of PGF2,, to PRP yielded corresponding increases upon radioimmunoassay (Fig. 3 ).
An Endoperoxide Intermediate and the Platelet Release Reaction 
Addition of collagen suspension to PRP induced changes similar to those noted with arachidonic acid (Fig. 5a) -0.5mM AA The correlation coefficient between the amount added and the amount found was 0.993, and the slope of the regression line was 1.00. Basal levels of PGFaa, in PRP were less than 0.5 pmol/ml. These levels were not increased when 1,000 pmol PGE3 was added to 2 ml PRP and extracted as described above. This demonstrates that PGE2 does not interfere with the estimation of PGF2a and that PGE2 is not reduced to PGF211, by treatment with stannous chloride.
Addition of varying amounts of PGE2 to PRP, followed by extraction, borohydride reduction, and radioimmunoassay yielded the expected increases.
RESULTS
When arachidonic acid was added to PRP, it induced irreversible platelet aggregation and the formation of PGE2 and PGF2a, which continued during the 5-min observation period (Fig. 4) We also observed that some release of these substances appeared to have occurred as early as 15 s after addition of collagen to PRP and at 2 min after epinephrine. Therefore, the formation of the endoperoxide intermediate is closely correlated with the platelet release reaction (9) .
In previous studies, newly formed PGE2 and PGF2a
were found outside the platelets 3 min after addition of collagen to PRP (4) . Experiments similar to the above showed that about 90% of the endoperoxide intermediate was present outside the platelets 1 min after collagen.
DISCUSSION
The distinguishing feature of the endoperoxide intermediate described by Hamberg and Samuelsson (1) is its ready convertibility to prostaglandins. Thus, while the compound spontaneously rearranges to PGE9 and 11-dehydro-PGF2a, its mild reduction with stannous chloride yields PGF24. The methods developed for measuring endoperoxide intermediate in the present study should be generally useful in investigations of its biological significance.
Our results show that an intermediate compound, reducible to PGF2r with stannous chloride, was formed not only when platelets were incubated with the prostaglandin precursor, arachidonic acid (Fig. 4) , but also when they were aggregated by collagen (Fig. 5) . During collagen-induced aggregation, ADP is released from platelets, as shown by other workers (17, 18) and by Table I . In addition, it has been shown that, although it does not inhibit primary ADP-induced aggregation, aspirin inhibits the release of ADP and aggregation induced by collagen (19) . These findings indicate that ADP release is necessary for aggregation by collagen. ADP is also released from platelets during the second wave of aggregation by epinephrine (11, and this paper). Both collagen and epinephrine induce the formation of PGE. and PGF25 (4) . The present studies indicate that this formation, like the release of ADP, begins before aggregation induced by collagen, but not until the second wave of aggregation by epinephrine. Therefore, the formation of prostaglandins is very closely related to the release of ADP.
Although PGE2 and PGF2. cause neither the release of ADP nor platelet aggregation (20) , their precursor, arachidonic acid, does (Table I and Fig. 4 ). This suggests that some intermediate or byproduct of their bio- (21) have recently described the formation of a "labile aggregating-stimulating substance" during incubation of arachidonic acid with a sheep seminal vesicle preparation. They found that arachidonic acid alone did not cause platelet aggregation, but this may be because their vehicle for arachidonic acid contained excess amounts of antioxidants. The aggregating factor they detected may be the endoperoxide intermediate.
There is now considerable evidence showing that tissues form and release prostaglandins in response to a variety of stimuli that disturb cell membranes (see reference 22). Our results suggest that the endoperoxide intermediate would also be released in response to such stimuli. Could this intermediate in prostaglandin biosynthesis be a previously unrecognized platelet-aggregating factor released from damaged tissues?
